Concepedia

Drew Rasco

DR

Statistics

Publications

90

Citations

7.7K

H-Index

40

Active since

2009

Affiliations

South Texas Accelerated Research Therapeutics(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

Sarah Cannon

Drew Rasco is an author at South Texas Accelerated Research Therapeutics specializing in medicine, oncology, and cancer therapeutics.

ORCID

Top concepts

Publications per year

2009–2024

90

Publications

90

Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Amita Patnaik, Soonmo Peter Kang, Drew Rasco et al. · Clinical Cancer Research · 2015 · 767 citations

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

Amita Patnaik, Lee S. Rosen, Sara M. Tolaney et al. · Cancer Discovery · 2016 · 740 citations · Full text

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

Branimir I. Šikić, Nehal J. Lakhani, Amita Patnaik et al. · Journal of Clinical Oncology · 2019 · 564 citations · Full text

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

Vicky Makker, Drew Rasco, Nicholas J. Vogelzang et al. · The Lancet Oncology · 2019 · 470 citations · Full text

, , +6

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors

Matthew H. Taylor, Chung‐Han Lee, Vicky Makker et al. · Journal of Clinical Oncology · 2020 · 446 citations · Full text

1–5 of 90